LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on MLYS stock, giving a Buy rating today.
Rami Katkhuda’s rating is based on the positive outcomes from Mineralys Therapeutics, Inc.’s pivotal studies on lorundrostat, which demonstrated significant reductions in systolic blood pressure in patients with uncontrolled and resistant hypertension. The Phase III Launch-HTN study showed a notable decrease in blood pressure with a low incidence of hyperkalemia, highlighting lorundrostat’s favorable risk/benefit profile compared to existing treatments like spironolactone.
Additionally, the Phase II Advance-HTN study further supported these findings with a substantial placebo-adjusted reduction in systolic blood pressure. The promising data suggest that lorundrostat could play a crucial role in later lines of treatment and potentially move into earlier treatment stages, despite potential payer restrictions. These factors collectively underpin Katkhuda’s Buy rating for Mineralys Therapeutics, Inc.’s stock.
Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Viridian Therapeutics, and VYNE Therapeutics. According to TipRanks, Katkhuda has an average return of 20.0% and a 41.56% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.